• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    uniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/13/25 5:27:13 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    000159056000-0000000false00015905602025-06-112025-06-11

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): June 11, 2025

    ​

    uniQure N.V.

    (Exact Name of Registrant as Specified in Charter)

    ​

    The Netherlands

      

    001-36294

      

    N/A

    (State or Other
    Jurisdiction of Incorporation)

    (Commission
    File Number)

    (IRS Employer
    Identification No.)

    ​

    Paasheuvelweg 25a,
    1105 BP Amsterdam, The Netherlands

      

    N/A

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    Registrant’s telephone number, including area code: +31-20-566-7394

    ​

    (Former Name or Former Address, if Changed Since Last Report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ​

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ​

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ​

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class:

      

    Trading Symbol(s)

      

    Name of each exchange on which registered:

    Ordinary Shares, par value €0.05 per share

    QURE

    The Nasdaq Stock Market LLC
    The Nasdaq Global Select Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    ​

    As described in Item 5.07, on June 11, 2025, at the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”), the shareholders of uniQure N.V. (the “Company”) approved an amendment to the Company’s Amended and Restated 2014 Share Incentive Plan (the “2014 Plan”) to increase the number of ordinary shares reserved for issuance thereunder (the “Plan Amendment”). The board of directors of the Company (the “Board”) approved the Plan Amendment on April 15, 2025, and directed that the Plan Amendment be submitted to a vote of the Company’s shareholders at the Annual Meeting. The Plan Amendment became effective immediately upon its approval by shareholders at the Annual Meeting.

    ​

    A description of the 2014 Plan and the Plan Amendment are set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on April 28, 2025 (“Proxy Statement”). The foregoing description of the material terms of the 2014 Plan and the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the 2014 Plan, as amended by the Plan Amendment, a conformed copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

    ​

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    ​

    On June 11, 2025, the Company held its Annual Meeting. There were 54,748,496 ordinary shares entitled to vote or be voted. 39,203,211 ordinary shares were voted in person or by proxy at the Annual Meeting.

    ​

    The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which are described in the Proxy Statement.

    ​

    Voting Proposal 1 - Resolution to adopt the 2024 Dutch statutory annual accounts and treatment of the results. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    34,060,570

    ​

    15,827

    ​

    5,909

    ​

    5,120,905

    ​

    Voting Proposal 2 - Resolution to discharge liability of the members of the Board. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,986,333

    ​

    75,344

    ​

    20,629

    ​

    5,120,905

    ​

    Voting Proposal 3 - Reappointment of Robert Gut as non-executive director. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,950,518

    ​

    106,055

    ​

    25,733

    ​

    5,120,905

    ​

    Voting Proposal 4 - Reappointment of Matthew Kapusta as executive director. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,948,169

    ​

    111,825

    ​

    22,312

    ​

    5,120,905

    ​

    Voting Proposal 5 - Reappointment of Jeremy Springhorn as non-executive director. This proposal was approved as set forth below.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    30,341,790

    ​

    3,709,321

    ​

    31,195

    ​

    5,120,905

    ​

    ​

    ​

    ​

    ​

    Voting Proposal 6 - Resolution to authorize sthe Board to issue ordinary shares and grant rights to subscribe for ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,902,912

    ​

    162,094

    ​

    17,300

    ​

    5,120,905

    ​

    Voting Proposal 7 - Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares and granting of rights to subscribe for ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,588,995

    ​

    476,539

    ​

    16,772

    ​

    5,120,905

    ​

    Voting Proposal 8 - Resolution to reauthorize the Board to repurchase ordinary shares. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    33,979,374

    ​

    92,426

    ​

    10,506

    ​

    5,120,905

    ​

    Voting Proposal 9 - Resolution to appoint KPMG Accountants N.V. as external auditors of the Company for the financial year 2025. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    39,177,095

    ​

    14,254

    ​

    11,862

    ​

    0

    ​

    Voting Proposal 10 - Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    32,363,219

    ​

    1,599,559

    ​

    119,528

    ​

    5,120,905

    ​

    Voting Proposal 11 - Resolution to approve the Plan Amendment and authorize the Board to issue ordinary shares and grant rights to subscribe for ordinary shares pursuant to the 2014 Plan (as amended by the Plan Amendment). This proposal was approved as set forth below.

    ​

    For

        

    Against

        

    Abstain

        

    Broker Non-Votes

    31,696,861

    ​

    2,105,666

    ​

    279,779

    ​

    5,120,905

    ​

    Based on the foregoing votes, the shareholders re-elected Matthew Kapusta as an executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting of shareholders of the Company, and approved all other proposals set forth on the agenda for the Annual Meeting.

    ​

    Item 9.01 Financial Statements and Exhibits

    ​

    (d)Exhibits

    ​

    ​

    ​

    ​

    Exhibit No.

    ​

    Description

    ​

    ​

    ​

    10.1

    ​

    Amended and Restated 2014 Share Incentive Plan of uniQure N.V. (conformed to include the Amendment to the Amended and Restated 2014 Share Incentive Plan attached as Appendix A to the Proxy Statement)

    ​

    ​

    ​

    104

    ​

    Cover Page Interactive Data File (embedded with the Inline XBRL document).

    ​

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    ​

     

    UNIQURE N.V.

     

     

     

     

     

    Date: June 13, 2025

    By:

    /s/ Jeannette Potts

     

     

    Jeannette Potts

     

     

    Chief Legal and Compliance Officer

    ​

    ​

    Get the next $QURE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    10/27/2021$66.00Outperform
    William Blair
    More analyst ratings